ANTI-HIV GENE THERAPY VECTORS
ANTI-HIV GENE THERAPY VECTORS
批准号:
10013746
负责人:
Anjali Joshi
金额:
$8.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-14 至 2020-07-31
关键词:
AddressAmino AcidsBerlinBindingBystander EffectCCR5 geneCD34 geneCD4 AntigensCD8B1 geneCXCR4 geneCell DeathCell LineCell TransplantationCell TransplantsCell surfaceCellsCessation of lifeClustered Regularly Interspaced Short Palindromic RepeatsCytoplasmic TailCytotoxic ChemotherapyCytotoxic T-LymphocytesEffectivenessEngraftmentEnsureGanciclovirGene DeliveryGene Transduction AgentGene therapy trialGenesHIVHIV InfectionsHIV ReceptorsHIV tat ProteinHIV-1Hematopoietic stem cellsHerpesviridaeHerpesvirus 1HumanImmune responseImmune systemIndividualInfectionKnock-outLeadLentivirus VectorLife Cycle StagesMediatingMethodologyMethodsModelingModificationPatientsPharmaceutical PreparationsReportingResistanceSafetySorting - Cell MovementStem cell transplantStem cellsSuicideSystemTK GeneTechnologyTestingThymidine KinaseTransplantationViralViral Load resultViral reservoirVirionVirusVirus LatencyVirus Replicationbasecell killingcombination gene therapycytotoxicdata modelinggene therapygenetically modified cellsin vivomathematical modelmutantnovelpreventsuccesssuicide genetargeted therapy trialstargeted treatmentvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Modifying stem cells by insertion of anti-HIV gene or gene editing technologies can theoretically result in an HIV
proof immune system in patients after stem cell transplantation. The success of the “Berlin patient” receiving
CCR5 negative cells for transplantation has demonstrated the feasibility of this approach. Thereafter, a myriad
gene therapy trials targeting CCR5 to prevent HIV entry have been tried with inconclusive results. Recent,
mathematical modeling data suggests that CCR5 disrupting strategies alone will fail to suppress HIV load unless
combined with a suicide gene. Thus, there is an urgent need to develop new combination gene therapy vectors
and methodologies that can be used to enrich vector modified stem cells before transplantation to ensure robust
engraftment. Our proposal addresses these issues via a two-step vector system that incorporates multiple safety
as well as selection features. Our vector 1 is a conditional vector that expresses the TK-SR39 gene only in the
presence of HIV Tat protein. TK-SR39 is a TK mutant that is highly potent at killing cells in the presence of small
amounts of Ganciclovir, a drug routinely used for Herpes virus treatment in HIV infected individuals. Furthermore,
our vector incorporates an added unique feature that it also transiently expresses a Tat inducible modified CD4
(CD4mod) that is a CD4 molecule lacking the cytoplasmic domain as well as HIV Env binding region. This will
provide a mechanism to purify modified cells using immunomagnetic beads while eliminating its use as a receptor
for HIV entry. To induce transient expression of CD4mod we will use vector 2 that expresses HIV Tat and a
CRISPR-CCR5 cassette to knockout CCR5. Thus, cells modified by this two-step vector system will have CCR5
knockout as well as conditional expression of TK-SR39 and CD4mod that will allow easy selection of cells. Thus,
these cells encompass multiple layers of anti-HIV activity as 1) because of CCR5 knock out they will resist HIV
infection 2) in case of CXCR4 virus emergence, the cytotoxic potential of TK-SR39 can be utilized via GCV
administration 3) this will lead to rapid death of infected cells thereby minimizing virus spread and preventing
establishment of latent reservoirs. The superiority of our approach lies in targeting the virus at multiple fronts and
allowing a method to sort modified cells that is the key to long-term engraftment in vivo.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/s12985-021-01501-7
发表时间:
2021-01-30
期刊:
Virology journal
影响因子:
4.8
作者:
[Mehmetoglu-Gurbuz T, Yeh R, Garg H, Joshi A]
通讯作者:
Joshi A
Role of SNARE proteins in HIV-1 assembly and release
-
批准号:8602832
-
项目类别:
-
资助金额:$7.55万
-
财政年份:2013
-
负责人:Anjali Joshi
-
依托单位:
Role of SNARE proteins in HIV-1 assembly and release
-
批准号:8466113
-
项目类别:
-
资助金额:$7.55万
-
财政年份:2013
-
负责人:Anjali Joshi
-
依托单位:
TARGETING THE VIRUS ASSEMBLY AND ENTRY PATHWAYS FOR ANTI-HIV GENE THERAPY
-
批准号:8262811
-
项目类别:
-
资助金额:$7.55万
-
财政年份:2012
-
负责人:Anjali Joshi
-
依托单位:
TARGETING THE VIRUS ASSEMBLY AND ENTRY PATHWAYS FOR ANTI-HIV GENE THERAPY
-
批准号:8527699
-
项目类别:
-
资助金额:$7.55万
-
财政年份:2012
-
负责人:Anjali Joshi
-
依托单位:
海外基金